Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Release
Shandong Lukang Pharmaceutical Co., Ltd. on 6ix
Earlier from Shandong Lukang Pharmaceutical
- Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Methocarbamol Injection and Becoming the Marketing Authorization Holder of the Drug
- Announcement on Canceling the Board of Supervisors and Amending the Articles of Association, and Revising, Formulating and Abolishing Some Goverance Systems
- Announcement on SSE Approval of Application for Issuance of Shares to Specific Objects
- Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection
- Announcement on Cefuroxime Axetil for Suspension Passing Consistency Evaluation
Later from Shandong Lukang Pharmaceutical
- Announcement on Resolutions of the 9th (Extraordinary) Meeting of the 11th Board of Supervisors
- Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Report for Q3 2025
- Announcement on the Company and Its Holding Subsidiaries Being Selected as Successful Bidders in the 11th Round of National Centralized Drug Procurement
Follow Shandong Lukang Pharmaceutical into a list and get an email when it puts out news.
Follow Shandong Lukang Pharmaceutical